0001209191-19-031531.txt : 20190520
0001209191-19-031531.hdr.sgml : 20190520
20190520183631
ACCESSION NUMBER: 0001209191-19-031531
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190516
FILED AS OF DATE: 20190520
DATE AS OF CHANGE: 20190520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bozigian Haig P.
CENTRAL INDEX KEY: 0001423837
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 19840376
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-16
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423837
Bozigian Haig P.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Common Stock
2019-05-16
4
M
0
22439
35.99
A
164415
D
Common Stock
2019-05-16
4
S
0
22439
80.128
D
141976
D
Common Stock
2019-05-16
4
M
0
9121
5.76
A
151097
D
Common Stock
2019-05-16
4
S
0
9121
80.128
D
141976
D
Common Stock
2019-05-16
4
M
0
34376
8.65
A
176352
D
Common Stock
2019-05-16
4
S
0
34376
80.128
D
141976
D
Common Stock
2019-05-16
4
M
0
731
19.59
A
142707
D
Common Stock
2019-05-16
4
S
0
731
80.128
D
141976
D
Non-Qualified Stock Option
35.99
2019-05-16
4
M
0
22439
35.99
D
2026-02-05
Common Stock
22439
9094
D
Non-Qualified Stock Option
5.76
2019-05-16
4
M
0
9121
5.76
D
2021-08-25
Common Stock
9121
0
D
Non-Qualified Stock Option
8.65
2019-05-16
4
M
0
34376
8.65
D
2023-01-10
Common Stock
34376
0
D
Non-Qualified Stock Option
19.59
2019-05-16
4
M
0
731
19.59
D
2024-01-16
Common Stock
731
57354
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted February 05, 2016 and vests monthly over four years.
Option granted August 25, 2011 and vested monthly over four years.
Option granted January 10, 2013 and vested monthly over four years.
Option granted January 16, 2014 and vested monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2019-05-20